Last updated Sunday, December 10, 2023
During the following months, he received the standard treatment for this type of tumor: radiation followed by chemotherapy. The tumor came back and continued to grow during the chemotherapy treatment (Temozolomide). His oncologist said further treatment would be useless.
He was lucky enough for another neuro-oncologist to agree to take over his care, so he was able to begin a new cycle of chemotherapy, this time CCNU (lomustine) and Tamoxifen (40mg/day), an antiestrogenic drug. The goal was to extend Jorge's life for a few months. It seemed a good deal at that time.
He altered his diet, reducing his intake of meat and steering clear of processed sugar whenever possible. Most days he'd drink a fresh vegetable juice or two. He had been taking melatonin π, 3 mg a day. His new oncologist agreed to continue supplementing melatonin and we increased the daily dose to 15mg. In addition, my research led me to try a supplement containing 'antineoplastons' (A10). We got it online via a webshop in the Netherlands. Dr. Valenzuela didn't object so Jorge started taking 18 A10 pills a day (3 x 6/day) about the same time he started the CCNU chemotherapy.
A new MRI, one month later, showed a slight reduction of the tumor. Jorge continued taking CCNU, Tamoxifen, Melatonin, and Aminocare A10 (Vitamin B-2 10.2 mg 600 L-Alanine 50.0 mg L-Arginine 54.0 mg Glycine 50.0 mg L-Ornithine 50.0 mg L-Glutamine Derivative (A10) 350.0 mg L-Serine 50.0 mg L-Threonine 50.0 mg L-Valine 50.0 mg per serving) and stayed on a sugar-free, meat-restricted diet. He was able to complete the 6-month CCNU treatment without any noticeable side effects.
By January 2004, the tumor was virtually gone and what was left was scar tissue.
Now,
Because Glioblastoma cures are so rare you're left wondering why the tumor disappeared.
A phase III trial, on the combination of bevacizumab and lomustine versus lomustine (CCNU) in patients with first progression of glioblastoma, resulted in a total of 8.8% of patients in the combination-therapy arm with no progression at 1 year, compared with 1.9% of patients in the lomustine-alone arm. Overall survival did not differ between the two study arms, with a median overall survival of only 8.6 months for the lomustine-alone study group and 9.1 months for the bevacizumab/lomustine study group.
In vitro, Tamoxifen is effective at killing glioma cells, yet several studies have not shown any benefit in overall survival. However, in one study of 38 patients with recurrent glioma, when suppressing thyroid gland activity to a low, but clinically tolerable level, it increases the effectiveness of tamoxifen, by lowering IGF-1 levels. To induce hypothyroidism, up to 1,000 mg of propylthiouracil daily and 30 mg of Lugol’s solution (Iodine) were given three times daily for 14 days. This is an interesting study in many ways. For instance, the use of Iodine π, which has apoptotic properties.
The case for supplementing Melatonin against Glioblastoma is getting stronger. New studies confirm the anticancer activity and synergy with chemotherapy {ref} of melatonin. Jorge kept taking melatonin, though intermittently, for a few years.
Ammonia can compete with phenylalanine for the enzymes involved in the formation of PA and PAG, leading to decreased formation of PA and PAG and increased levels of phenylalanine in the body, in line with the levels observed in cancer patients {ref|ref}.
In 2002, the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL informed of the complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. The patient in this study took 3 daily doses of Phenylbutyrate orally, for a total of 18 grams a day.
In 2016, a study found that Phenylbutyrate suppresses the proliferation of glioblastoma LN-229 cell line.
Phenylbutyrate is an HDAC inhibitor, a chemical compound that may block tumor cell proliferation.
Probably just as important, oral phenylbutyrate can be used as a “glutamine trap” to create a model of glutamine/ammonia depletion π {study|hypothesis}.
Hence we have scientific studies confirming the anti-cancer activity of antineoplastons, by way of an orally administered powder, Phenylbutyrate.
Note that Burzinsky is currently prohibited to sell antineoplastons, and although Aminocare A10 is still available, the formula has changed and no longer contains antineoplastons. But Sodium Phenylbutyrate (Buphenyl) should be available off-label.
Update: Jorge's last MRI was in November 2023, and all clear. MRI is available upon request (please use the comment section below to contact me).
Complementary and Alternative Medicine (CAM) for Glioblastoma (Integrative Therapies)
1. Supplements
glioblastoma (xenograft mouse model)
Temozolomide (TMZ) vs Honokiol (Hono) and/or
Magnolol (Mag)
Honokiol π {study| study} + Magnolol π - Artemisinin π {study}
- Citric acid π {study}
- Quercetin + Butyrateπ: {study}
- L-ornithine -L-aspartate {ref} protective effect on the development of encephalopathy and brain edema
- Vitamin D3: {study | ref}
- Shikonin {study}
- Combination of Natural Supplements as Adjunct Cancer Therapy
- Curcumin: {study|study|study}} Preferably preparations of high bioavailability curcumin
- → Butyrate π {study}
- → Boswellic acid π:{study}
- → Berberine: {study|study}
- → Sulforaphane {study} → Sodium selenite {study}
- → Bacopa monnieri {study}
- → Lycopene
- Ruta 6 (homeopathy) {product link / FAQ link}
- Taurine {ref}
- Royal Jelly: contains Phenylbutyrate {study|study|study}
- Baicalein
- Curcuma Amada (mango ginger) {study}
- → Humulus Lupulus {study}
- EGCg
- Ursolic acid: {study} UA is a natural FAS inhibitor
- Luteolin: {study}
- → Silibinin
- Betulinic acid: {study|study}
- Cucurbitacin d: A natural BCAT1 inhibitor; may have promising clinical potential in the treatment of Glioblastoma {study}. Watermelon and melon are good dietary sources of this compound.
- Riboflavin (Vit.B2) Suggested short-term dose: 50-100mg/day
- Resolvins: metabolic byproducts of omega-3 fatty acids, primarily EPA, DHA, and DPA {study}
- Cannabigerol {review}
- Gamma-Linolenic acid
- Theobromine {study}
- → Chlorogenic acid π
- Salvia miltiorrhiza π {study}
- Thymoquinone
- Piperlongumine {study}
- Juglone (black walnut) {study}
- Paeoniflorin {ref}
- Grapeseed extract (may improve drug delivery through BBB?)
→: Possible synergistic effects
glioblastoma (xenograft mouse model) Temozolomide (TMZ) vs Honokiol (Hono) and/or Magnolol (Mag) |
- → Butyrate π {study}
- → Boswellic acid π:{study}
- → Berberine: {study|study}
- → Sulforaphane {study} → Sodium selenite {study}
- → Bacopa monnieri {study}
- → Lycopene
- → Humulus Lupulus {study}
- → Silibinin
2. Repurposed drugs π
- Phenylbutyrate (Sodium Phenylbutyrate (4-PBA) Powder) or Glycerol phenylbutyrate (Ravicti)
- Chloroquine (see below)
- COC protocol {ref}
- Celecoxib + sildenafil (PDE5 Inhibitor) {ref}
- Methylene blue {ref | link | link} drug info MB IV (contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency)
- Mebendazole {study|article}
- Melatonin + Albendazole {ref}
- Repurposed Drugs by Stephen Western Astrocytoma Options.com
- Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
- Niclosamide + camptothecin {study}
- Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists {ref}
- Drug repositioning: Using psychotropic drugs for the treatment of glioma {ref}
- Bumetanide: NKCC1 Regulates Migration Ability of Glioblastoma Cells by Modulation of Actin Dynamics and Interacting with Cofilin {ref}
- Cyproheptadine {ref}
- Sulconazole {ref} "An in-depth investigation of this compound revealed that it competes with biotin (Vitamin H), an important co-factor for metabolic enzymes and modifier of histones, allowing it to inhibit the normal function of biotin-dependent metabolic enzymes and specific histone modification-associated gene expression. Since biotin is found in various food sources, including legumes, egg yolk and offal, and commonly consumed as a supplement, these findings raise an important consideration of regulating biotin consumption in glioblastoma patients."
- Posaconazole {ref}
- Phenylbutyrate (Sodium Phenylbutyrate (4-PBA) Powder) or Glycerol phenylbutyrate (Ravicti)
- Chloroquine (see below)
- COC protocol {ref}
- Celecoxib + sildenafil (PDE5 Inhibitor) {ref}
- Methylene blue {ref | link | link} drug info MB IV (contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency)
- Mebendazole {study|article}
- Melatonin + Albendazole {ref}
- Repurposed Drugs by Stephen Western Astrocytoma Options.com
- Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
- Niclosamide + camptothecin {study}
- Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists {ref}
- Drug repositioning: Using psychotropic drugs for the treatment of glioma {ref}
- Bumetanide: NKCC1 Regulates Migration Ability of Glioblastoma Cells by Modulation of Actin Dynamics and Interacting with Cofilin {ref}
- Cyproheptadine {ref}
- Sulconazole {ref} "An in-depth investigation of this compound revealed that it competes with biotin (Vitamin H), an important co-factor for metabolic enzymes and modifier of histones, allowing it to inhibit the normal function of biotin-dependent metabolic enzymes and specific histone modification-associated gene expression. Since biotin is found in various food sources, including legumes, egg yolk and offal, and commonly consumed as a supplement, these findings raise an important consideration of regulating biotin consumption in glioblastoma patients."
- Posaconazole {ref}
Synergistic combinations of natural compounds and drug repurposingFor information purposes only, nothing I write is medical advice.
Strategy - an integrative approach to cancer management: example of a multi-layered approach using coactive combinations of natural substances and drug repurposing.
click to enlarge the diagram
Synergistic combinations of natural compounds and drug repurposing
For information purposes only, nothing I write is medical advice.
Strategy - an integrative approach to cancer management: example of a multi-layered approach using coactive combinations of natural substances and drug repurposing.
click to enlarge the diagram |
Promising experimental treatments for Glioblastoma
➤ DELYTACT (Japan) "In this G47∆ phase 2 trial, the median OS was 28.8 months from the initial surgery."
➤ Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Median survival after surgery was 24 months for chloroquine-treated patients and 11 months for controls. https://www.ncbi.nlm.nih.gov/pubmed/16520474
- Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy {ref}
- Quercetin and chloroquine synergistically kill glioma cells by inducing organelle stress and disrupting Ca2+ homeostasis {ref}
➤ Salinomycin with 2DG - More info on this treatment here
➤ Poliovirus Therapy (Duke Cancer Institute)➤ GSK3Ξ² inhibitor kenpaullone as a temozolomide enhancer against Glioblastoma
- (MAY 29, 2018) NW Bio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
- Testimonial long term survivor (video)
- Presentation (video)
➤ LAMP-pp65-DC Vaccine - Clinical trial (recruiting)
➤ Combined treatment of 2-DG analogs and
modulation of histone deacetylases (HDAC) activity via HDAC inhibitors (sodium butyrate and
sodium valproate) exerts synergistic cytotoxic effects in glioblastoma U-87 and U-251 cells and
represents a promising therapeutic strategy {study}
➤ Gallium maltolate in glioblastoma cells is enhanced by metformin through combined action on mitochondrial complex 1 {study}
➤ Poliovirus Therapy (Duke Cancer Institute)
➤ GSK3Ξ² inhibitor kenpaullone as a temozolomide enhancer against Glioblastoma
- (MAY 29, 2018) NW Bio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
- Testimonial long term survivor (video)
- Presentation (video)
➤ LAMP-pp65-DC Vaccine
- Clinical trial (recruiting)
➤ Combined treatment of 2-DG analogs and
modulation of histone deacetylases (HDAC) activity via HDAC inhibitors (sodium butyrate and
sodium valproate) exerts synergistic cytotoxic effects in glioblastoma U-87 and U-251 cells and
represents a promising therapeutic strategy {study}
➤ Synergistic role of thymoquinone and 5-fluorouracil in U-251MG glioblastoma cell line {study}
➤ Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide {ref}
References & Sources
References & Sources
- Missing immune cells that could fight lethal brain tumors - A mysterious lack of T-cells has hindered the immune system's ability to fight glioblastoma
- Lin H, Patel S, Affleck VS, Wilson I, Turnbull DM, Joshi AR, Maxwell R, Stoll EA. Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro-Oncology 2017, 19(1), 43-54.
- Study explains mechanisms behind glioblastoma influence on the immune system
- PDF Targeting cellular pathways in glioblastoma multiforme
- Beating the odds: extreme long-term survival with glioblastoma
- Lomustine/Bevacizumab Fails to Improve Survival in Recurrent Glioblastoma
- (2016) EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma
- A very rare case report of long-term survival: A patient operated on in 1994 of glioblastoma multiforme and currently in perfect health
- Burzynski: Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.
- (1996) Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma
- Burzynski: Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme
- Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells
- (2005) Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
- Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma
- https://pubchem.ncbi.nlm.nih.gov/compound/Antineoplaston_A10#section=3D-Conformer
- https://www.drugbank.ca/drugs/DB11702
- https://www.researchgate.net/publication/295993966_Toxicology_studies_on_oral_formulation_of_antineoplaston_A10_in_cancer_patients
- https://medkoo.com/products/12061
- http://www.aetna.com/cpb/medical/data/200_299/0240.html
- https://www.cancertutor.com/antineo/
- https://www.drweil.com/health-wellness/body-mind-spirit/cancer/antineoplastons-a-bogus-cancer-treatment/
- http://www.burzynskipatientgroup.org/
- https://theotherburzynskipatientgroup.wordpress.com/
- https://sciencebasedmedicine.org/stanislaw-burzynski-antineoplastons-and-the-orphan-drug-sodium-phenyl-butyrate/
- http://www.burzynskiclinic.com
- (1996) Increased Survival Time in Brain Glioblastomas by a Radioneuroendocrine Strategy with Radiotherapy plus Melatonin Compared to Radiotherapy Alone
- (2016) Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis
- (2017) Melatonin Inhibits Glioblastoma Stem-like cells through Suppression of EZH2-NOTCH1 Signaling Axis
- https://www.ncbi.nlm.nih.gov/pubmed/23898108
- https://www.nature.com/articles/sigtrans201740
- https://academic.oup.com/neuro-oncology/article/8/1/47/1101009
- https://virtualtrials.com/Tam1.cfm
- http://www.cancernetwork.com/articles/hypothyroidism-enhances-high-dose-tamoxifen-glioma
- http://virtualtrials.com/pdf/friedman.pdf
- https://www.nature.com/articles/bjc2015421
- http://pediamecum.es/wp-content/farmacos/Fenilbutirato.pdf
- https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-9-95
- Antitumor activity of CDA‑Ⅱ, a urinary preparation, on human multiple myeloma cell lines via the mitochondrial pathway
- Phenylacetylglutaminate and Phenylacetate in Combination Upregulate VDUP1, Cause Cell Cycle Blockade and Apoptosis in U87 Glioblastoma Cells
- https://virtualtrials.com/pdf2017/treatment_options_gbm_2017.pdf
- Complementary therapy and survival in glioblastoma
- Synergism of Quercetin and Sodium Butyrate for Controlling Growth of Glioblastoma
- Cucurbitacin D, found in watermelon, decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene
- A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities {ref}
- Basics of immunobiology
- L-Ornithine and Phenylacetate Synergistically Produce Sustained Reduction in Ammonia and Brain Water in Cirrhotic Rats {ref}
- L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure {ref}
- Ammonia effects on pyruvate/lactate production in astrocytes—Interaction with glutamate{ref}
- The Cahill cycle
- "melatonin exhibited neuroprotective effects by increasing the enzyme activity involved in ammonia detoxification, by controlling liver enzymes, and by inhibiting ammonia’s entry into the brain by maintaining BBB integrity." {study}
- Cancer cell intrinsic TIM-3 induces glioblastoma progression
- Natural bioactive molecules: An alternative approach to the treatment and control of glioblastoma multiforme {ref}
- Recent advances in glioblastoma multiforme therapy: A focus on autophagy regulation {ref}
- Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment {ref}
- Zhao et al. identified lymphatic endothelial-like cells in glioblastoma and demonstrated their role in promoting tumour growth through increased glioblastoma cholesterol metabolism. {study}
* Solely intended for informational use, none of my writing constitutes medical advice.
Thanks for writing this important report!
ReplyDeleteDo you have an opinion on what dose of sodium phenylbutyrat would be sufficient? 18 grams / day would be ~$1500 / month, which is a bit out of reach for me.
I've included a link to a generic (and cheaper) option here: https://synergiesforcancertreatments.blogspot.com/p/butyrate.html
DeleteI would start at 4grams a day, and up-titrate if needed.
THANK UOU
ReplyDelete